pioglitazone has been researched along with Hyperplasia in 12 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Hyperplasia: An increase in the number of cells in a tissue or organ without tumor formation. It differs from HYPERTROPHY, which is an increase in bulk without an increase in the number of cells.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment of pioglitazone reduced neointimal hyperplasia in patients with STEMI treated with primary stent implantation without placing the patient at increased risk of complications." | 9.14 | Efficacy and safety of pioglitazone in patients with ST elevation myocardial infarction treated with primary stent implantation. ( Domae, H; Kaneda, H; Matsumi, J; Minami, Y; Miyashita, Y; Mizuno, S; Saito, S; Shiono, T; Sugitatsu, K; Takahashi, S; Taketani, Y, 2009) |
| "This study investigates whether pioglitazone reduces neointimal hyperplasia after coronary stenting in nondiabetic patients with metabolic syndrome (MS) using intravascular ultrasound (IVUS)." | 9.12 | Reduction of neointimal hyperplasia after coronary stenting by pioglitazone in nondiabetic patients with metabolic syndrome. ( Katayama, T; Kawakami, M; Kubo, N; Kuroki, M; Momomura, S; Saito, M; Tsuboi, K; Ueba, H; Yasu, T, 2007) |
| "Treatment with pioglitazone markedly inhibited intimal hyperplasia of carotid interposition-reversed jugular vein grafts in the pioglitazone group (0." | 7.77 | Pioglitazone prevents intimal hyperplasia in experimental rabbit vein grafts. ( Komori, K; Maehara, Y; Morisaki, K; Murohara, T; Ouchi, N; Shibata, R; Takahashi, N, 2011) |
| " PPAR-gamma agonists like pioglitazone decrease insulin resistance and have been shown to reduce neointimal hyperplasia in the short-term." | 7.74 | Long-term effects of a PPAR-gamma agonist, pioglitazone, on neointimal hyperplasia and endothelial regrowth in insulin resistant rats. ( Desouza, CV; Gerety, M; Hamel, FG, 2007) |
| " We have investigated the role of pioglitazone in the apoptosis of vascular smooth muscle cells (VSMCs) in vitro and developed intimal hyperplasia in vivo." | 7.71 | Pioglitazone enhances cytokine-induced apoptosis in vascular smooth muscle cells and reduces intimal hyperplasia. ( Aizawa, Y; Hasebe, N; Kawabe , J; Kikuchi, K; Takehara, N, 2001) |
| "Treatment of pioglitazone reduced neointimal hyperplasia in patients with STEMI treated with primary stent implantation without placing the patient at increased risk of complications." | 5.14 | Efficacy and safety of pioglitazone in patients with ST elevation myocardial infarction treated with primary stent implantation. ( Domae, H; Kaneda, H; Matsumi, J; Minami, Y; Miyashita, Y; Mizuno, S; Saito, S; Shiono, T; Sugitatsu, K; Takahashi, S; Taketani, Y, 2009) |
| "This study investigates whether pioglitazone reduces neointimal hyperplasia after coronary stenting in nondiabetic patients with metabolic syndrome (MS) using intravascular ultrasound (IVUS)." | 5.12 | Reduction of neointimal hyperplasia after coronary stenting by pioglitazone in nondiabetic patients with metabolic syndrome. ( Katayama, T; Kawakami, M; Kubo, N; Kuroki, M; Momomura, S; Saito, M; Tsuboi, K; Ueba, H; Yasu, T, 2007) |
| " PPAR-gamma agonists like pioglitazone decrease insulin resistance and have been shown to reduce neointimal hyperplasia in the short-term." | 3.74 | Long-term effects of a PPAR-gamma agonist, pioglitazone, on neointimal hyperplasia and endothelial regrowth in insulin resistant rats. ( Desouza, CV; Gerety, M; Hamel, FG, 2007) |
| "Pioglitazone prolongs allograft survival and attenuates neointimal hyperplasia through the suppression of proliferation of smooth muscle cells." | 3.73 | Pioglitazone prevents acute and chronic cardiac allograft rejection. ( Haraguchi, G; Isobe, M; Koga, N; Kosuge, H; Maejima, Y; Suzuki, J, 2006) |
| " We have investigated the role of pioglitazone in the apoptosis of vascular smooth muscle cells (VSMCs) in vitro and developed intimal hyperplasia in vivo." | 3.71 | Pioglitazone enhances cytokine-induced apoptosis in vascular smooth muscle cells and reduces intimal hyperplasia. ( Aizawa, Y; Hasebe, N; Kawabe , J; Kikuchi, K; Takehara, N, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (41.67) | 29.6817 |
| 2010's | 6 (50.00) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Assmann, AK | 1 |
| Winnicki, V | 1 |
| Sugimura, Y | 1 |
| Chekhoeva, A | 1 |
| Barth, M | 1 |
| Assmann, A | 1 |
| Lichtenberg, A | 1 |
| Akhyari, P | 1 |
| Hong, SJ | 2 |
| Choi, SC | 1 |
| Cho, JY | 1 |
| Joo, HJ | 1 |
| Park, JH | 2 |
| Yu, CW | 1 |
| Lim, DS | 2 |
| Kaneda, H | 1 |
| Shiono, T | 1 |
| Miyashita, Y | 1 |
| Takahashi, S | 1 |
| Taketani, Y | 1 |
| Domae, H | 1 |
| Matsumi, J | 1 |
| Mizuno, S | 1 |
| Minami, Y | 1 |
| Sugitatsu, K | 1 |
| Saito, S | 1 |
| Chen, Z | 1 |
| Hasegawa, T | 1 |
| Tanaka, A | 1 |
| Okita, Y | 1 |
| Okada, K | 1 |
| Kim, ST | 1 |
| Kim, TJ | 1 |
| Kim, EO | 1 |
| Ahn, CM | 1 |
| Kim, JS | 1 |
| Lee, KM | 1 |
| Tsyriuk, OI | 1 |
| Morisaki, K | 1 |
| Shibata, R | 1 |
| Takahashi, N | 1 |
| Ouchi, N | 1 |
| Maehara, Y | 1 |
| Murohara, T | 1 |
| Komori, K | 1 |
| Li, MY | 1 |
| Kong, AW | 1 |
| Yuan, H | 1 |
| Ma, LT | 1 |
| Hsin, MK | 1 |
| Wan, IY | 1 |
| Underwood, MJ | 1 |
| Chen, GG | 1 |
| Kosuge, H | 1 |
| Haraguchi, G | 1 |
| Koga, N | 1 |
| Maejima, Y | 1 |
| Suzuki, J | 1 |
| Isobe, M | 1 |
| Desouza, CV | 1 |
| Gerety, M | 1 |
| Hamel, FG | 1 |
| Katayama, T | 1 |
| Ueba, H | 1 |
| Tsuboi, K | 1 |
| Kubo, N | 1 |
| Yasu, T | 1 |
| Kuroki, M | 1 |
| Saito, M | 1 |
| Momomura, S | 1 |
| Kawakami, M | 1 |
| Aizawa, Y | 1 |
| Kawabe , J | 1 |
| Hasebe, N | 1 |
| Takehara, N | 1 |
| Kikuchi, K | 1 |
4 trials available for pioglitazone and Hyperplasia
| Article | Year |
|---|---|
Pioglitazone increases circulating microRNA-24 with decrease in coronary neointimal hyperplasia in type 2 diabetic patients- optical coherence tomography analysis.
Topics: Aged; Coronary Vessels; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Humans; Hyperplasi | 2015 |
Efficacy and safety of pioglitazone in patients with ST elevation myocardial infarction treated with primary stent implantation.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Coronary Angiography; Coronary Restenosis; | 2009 |
Cellular and molecular changes associated with inhibitory effect of pioglitazone on neointimal growth in patients with type 2 diabetes after zotarolimus-eluting stent implantation.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Biomarkers; Blood Glucose; Cardiovascular Agents; Cell | 2010 |
Reduction of neointimal hyperplasia after coronary stenting by pioglitazone in nondiabetic patients with metabolic syndrome.
Topics: Coronary Restenosis; Coronary Vessels; Female; Follow-Up Studies; Humans; Hyperplasia; Hypoglycemic | 2007 |
8 other studies available for pioglitazone and Hyperplasia
| Article | Year |
|---|---|
Impact of PPAR-gamma activation on the durability of biological heart valve prostheses in hypercholesterolaemic rats.
Topics: Animals; Heart Valve Prosthesis; Hypercholesterolemia; Hyperplasia; Obesity; Pioglitazone; PPAR gamm | 2022 |
Pioglitazone preserves vein graft integrity in a rat aortic interposition model.
Topics: Administration, Oral; Anastomosis, Surgical; Animals; Aorta, Abdominal; Blood Flow Velocity; Dilatat | 2010 |
[Correction of negative influence of long-term hypergastrinemia on gastric acid secretion].
Topics: Animals; Anti-Ulcer Agents; Drug Therapy, Combination; Gastric Acid; Gastric Mucosa; Gastrins; Hyper | 2011 |
Pioglitazone prevents intimal hyperplasia in experimental rabbit vein grafts.
Topics: Animals; Carotid Artery, Common; Hyperplasia; Hypoglycemic Agents; Jugular Veins; Male; Models, Anim | 2011 |
Pioglitazone prevents smoking carcinogen-induced lung tumor development in mice.
Topics: Animals; Anticarcinogenic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Transformati | 2012 |
Pioglitazone prevents acute and chronic cardiac allograft rejection.
Topics: Animals; Cell Proliferation; Cells, Cultured; Chemokine CCL2; Gene Expression Regulation; Graft Reje | 2006 |
Long-term effects of a PPAR-gamma agonist, pioglitazone, on neointimal hyperplasia and endothelial regrowth in insulin resistant rats.
Topics: Animals; Endothelium, Vascular; Female; Hyperplasia; Hypoglycemic Agents; Insulin Resistance; Piogli | 2007 |
Pioglitazone enhances cytokine-induced apoptosis in vascular smooth muscle cells and reduces intimal hyperplasia.
Topics: Animals; Apoptosis; Carotid Arteries; Carotid Artery Injuries; Catheterization; Cell Division; Cell | 2001 |